Across the global pharmaceutical landscape, an estimated 5,000 potential treatments for rare diseases are currently languishing on corporate shelves, representing…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The biopharmaceutical industry, in its relentless pursuit of innovation and efficiency, faces a silent but profound challenge: the erosion of…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s.
A significant stride in the realm of integrated medicine has been reported by Remepy, a pioneering startup, as its innovative…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant paradigm shift is underway in the pharmaceutical industry’s approach to small-molecule drug discovery, as a new collaborative platform,…
Read More
Blazing new paths for biotech
The landscape for American biotechnology firms has undergone a profound transformation in recent years, shifting from a period of robust…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
ADA Conference Unveils Groundbreaking GLP-1 Advances Amidst Controversy Over Scientific Dissent
The annual scientific sessions of the American Diabetes Association (ADA) this week served as a pivotal platform for significant announcements…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
A decade in the making: How functional NAMs are redefining cardiac safety assessment
In recent years, the pharmaceutical industry has witnessed a dramatic acceleration in the adoption of New Approach Methodologies (NAMs) for…
Read MoreYOU MAY HAVE MISSED
